Role of HDAC6 inhibition in sepsis-induced acute respiratory distress syndrome (Review)

xlomafota13 shared this article with you from Inoreader Role of HDAC6 inhibition in sepsis-induced acute respiratory distress syndrome (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 May;21(5):422. doi: 10.3892/etm.2021.9866. Epub 2021 Feb 25. ABSTRACT Acute respiratory distress syndrome (ARDS) induced by sepsis contributes remarkably to the high mortality rate observed in intensive care units, largely due to a lack of effective drug therapies. Histone deacetylase 6 (HDAC6) is a class-IIb deacetylase that modulates non-nuclear protein functions via deacetylation and ubiquitination. Importantly, HDAC6 has been shown to exert anti-cancer, anti-neurodegeneration, and immunological effects, and several HDAC6 inhibitors have now entered clinical trials. It has also been recently shown to modulate inflammation, and HDAC6 inhibition has been demonstrated to markedly suppress experimental sepsis. The present review summarizes the role of HDAC6 in sepsis-induced inflammation and endothelial barrier dysfunction in recent years. It is proposed that HDAC6 inhibition predominantly ameliorates sepsis-induced A RDS by directly attenuating inflammation, which modulates the innate and adaptive immunity, transcription of pro-inflammatory genes, and protects endothelial barrier function. HDAC6 inhibition protects against sepsis-induced ARDS, thereby making HDAC6 a promising therapeutic target. However, HDAC inhibition may be associated with adverse effects on the embryo sac and oocyte, necessitating further studies. PMID:33747162 | PMC:PMC7967812 | DOI:10.3892/etm.2021.9866 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.